# OnCo record oak (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/oak/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "oak", "NCT02008227" ;
  schema:name "OAK"@en ;
  schema:description "The trial that put a PD-L1 antibody alongside the PD-1 antibodies as second-line treatment for lung cancer, in the largest second-line immunotherapy trial run."@en ;
  schema:url <https://onco.cc/trials/oak/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02008227>, <https://doi.org/10.1016/S0140-6736(16)32517-X>, <https://www.nice.org.uk/guidance/ta520> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-squamous-cell-carcinoma/>, <https://onco.cc/cancers/lung-adenocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/immune-checkpoint/>, <https://onco.cc/terms/pd-l1-testing/> ;
  onco:trials <https://onco.cc/trials/checkmate-017/>, <https://onco.cc/trials/checkmate-057/> .